Kwon J, et al. - Experts explored the outcomes of portal vein thrombosis (PVT) treatment with low-molecular-weight heparin (LMWH) in patients with liver cirrhosis (LC), with a median age of 62.9 years who were given dalteparin or enoxaparin for six months. Exclusion criteria involved subjects with major bleeding during the last 3 months, severe thrombocytopenia or impaired renal function. It was discovered that individuals with a favorable Child-Pugh class and those recently diagnosed as having a thrombus exhibited significantly better responses. LMWH therapy for PVT in LC was found to be effective. It was noted that the effect of LMWH was decreased via advanced LC and a delayed start of anticoagulation treatment. A risk of hemorrhage was reported despite its effectiveness. Therefore, data recommended cautious consideration of anticoagulation, especially in patients with advanced LC and a history of variceal bleeding.